pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
308
stories
18d
Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
fiercebiotech
18d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
21d
Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M
endpoints
21d
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s
biopharma dive
22d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
22d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
22d
Stability, speed and strategy: Inside Australia’s early‑stage edge
biospace
22d
Opinion: Health care needs buyers willing to say no
stat
22d
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
23d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
23d
FDA’s rare disease framework aims to ‘stand the test of time’
fiercebiotech
23d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
23d
What has actually caused the decline in drug overdose deaths?
stat
23d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
23d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
23d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
23d
Have you been impacted by Epic’s actions?
stat
24d
Ferring to acquire next-gen IVF startup Gameto for up to $1.4B
biopharma dive
24d
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
stat
24d
‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 days
fiercebiotech
24d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
24d
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
biospace
24d
Artiva to wind down after two patient deaths in autoimmune cell therapy trials
endpoints
24d
Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO
endpoints
24d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
24d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
24d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
25d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
25d
Australia's clinical trial advantage gains ground amid U.S. uncertainty
biospace
28d
Q&A: Bristol Myers' Lynelle Hoch on autoimmune CAR-T safety challenges
endpoints
← prev
page 2 of 11
next →